Results 141 to 150 of about 3,209,093 (279)

Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Real‐world initial treatment strategies in systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analyzed treatment‐naive patients with SSc‐PAH from the European
Hilde Jenssen Bjørkekjær   +63 more
wiley   +1 more source

Semaphorin 4A Neutralization Reduces Fibrosis and Inflammation in a Mouse Model of Systemic Sclerosis and a 3D Model of Immunity‐Driven Fibrosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective We previously showed that Semaphorin 4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by enzyme‐linked immunosorbent assay in healthy controls (n =
Jaime Marty   +21 more
wiley   +1 more source

Clinical Effectiveness of Continuous Pressure Monitoring Systems for Pressure Ulcer Prevention: A Scoping Review. [PDF]

open access: yesInt Wound J
Hoque R   +13 more
europepmc   +1 more source

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight‐related comorbidity at the week 36 primary end point. The
Joseph F. Merola   +14 more
wiley   +1 more source

Wound, Pressure Ulcer, and Burn Guidelines (2023)-6: Guidelines for the Management of Burns, Third Edition. [PDF]

open access: yesJ Dermatol
Yoshino Y   +24 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

NEW PROTOCOL FOR IAD TREATMENT IN PEDIATRIC PATIENTS: STABLE OZONIDES

open access: yes
NEW PROTOCOL FOR IAD TREATMENT IN PEDIATRIC PATIENTS: STABLE OZONIDES Serena Crucianelli1 , Guido Ciprandi2 , Mauro Pace3 , Valentina Vanzi4 , Monica Rossi5 , Giancarlo Antonielli6 1 Sapienza University of Rome, Internal Medicine and Medical ...
SERENA CRUCIANELLI   +5 more
core  

Home - About - Disclaimer - Privacy